Evidence map›Paper›PMID 38556574›Full record

ArticleActa neuropathologica2024

Microglial phagolysosome dysfunction and altered neural communication amplify phenotypic severity in Prader-Willi Syndrome with larger deletion.

Felipe Correa-da-Silva, Jenny Carter, Xin-Yuan Wang, Rui Sun, Ekta Pathak, José Manuel Monroy Kuhn, Sonja C Schriever, Clarissa M Maya-Monteiro, Han Jiao, Martin J Kalsbeek and 15 more

Open access · hybridAbstract read
In one paragraph

Article in Acta neuropathologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 8 institutions in 5 countries.

Felipe Correa-da-SilvaDepartment of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location AMC. University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
Jenny CarterNeuroscience and Mental Health Innovation Institute, MRC Centre for Neuropsychiatric Genetic and Genomics, School of Medicine, Cardiff University, Cardiff, UK.
Xin-Yuan WangKey Laboratory of Cardiovascular and Cerebrovascular Medicine, School of Pharmacy, Nanjing Medical University, Nanjing, China.
Rui SunKey Laboratory of Cardiovascular and Cerebrovascular Medicine, School of Pharmacy, Nanjing Medical University, Nanjing, China.
Ekta PathakComputational Discovery Unit, Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.
José Manuel Monroy KuhnComputational Discovery Unit, Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.
Sonja C SchrieverGerman Center for Diabetes Research (DZD), Neuherberg, Germany.
Clarissa M Maya-MonteiroDepartment of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location AMC. University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
Han JiaoDepartment of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location AMC. University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
Martin J KalsbeekDepartment of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location AMC. University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
Pedro M M Moraes-VieiraLaboratory of Immunometabolism, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, São Paulo, Brazil.
Johan J P GilleDepartment of Clinical Genetics, Amsterdam University Medical Centers, location VUMC. University of Amsterdam, Amsterdam, The Netherlands.
Margje SinnemaDepartment of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.
Constance T R M StumpelDepartment of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands.
Leopold M G CurfsGovernor Kremers Centre, Maastricht University Medical Centre, Maastricht, The Netherlands.
Dirk Jan StenversDepartment of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location AMC. University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
Paul T PflugerGerman Center for Diabetes Research (DZD), Neuherberg, Germany.
Dominik LutterComputational Discovery Unit, Institute for Diabetes and Obesity, Helmholtz Zentrum München, Neuherberg, Germany.
Alberto M PereiraDepartment of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location AMC. University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
Andries KalsbeekDepartment of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location AMC. University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
Eric FliersDepartment of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location AMC. University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
Dick F SwaabNetherlands Institute for Neuroscience, Amsterdam, The Netherlands.
Lawrence WilkinsonNeuroscience and Mental Health Innovation Institute, MRC Centre for Neuropsychiatric Genetic and Genomics, School of Medicine, Cardiff University, Cardiff, UK.
Yuanqing GaoKey Laboratory of Cardiovascular and Cerebrovascular Medicine, School of Pharmacy, Nanjing Medical University, Nanjing, China.
Chun-Xia YiDepartment of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location AMC. University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands. c.yi@amsterdamumc.nl.ORCID 0000-0003-1184-4615
Amsterdam University Medical Centers · NLHelmholtz Zentrum München · DENetherlands Institute for Neuroscience · NLNanjing Medical University · CNCardiff University · GBMaastricht University · NLMaastricht University Medical Centre · NLUniversidade Estadual de Campinas (UNICAMP) · BR

Funding

Diabetes Fonds 2015.82.1826
6 · The paper itself

Abstract

Prader-Willi Syndrome (PWS) is a rare neurodevelopmental disorder of genetic etiology, characterized by paternal deletion of genes located at chromosome 15 in 70% of cases. Two distinct genetic subtypes of PWS deletions are characterized, where type I (PWS T1) carries four extra haploinsufficient genes compared to type II (PWS T2). PWS T1 individuals display more pronounced physiological and cognitive abnormalities than PWS T2, yet the exact neuropathological mechanisms behind these differences remain unclear. Our study employed postmortem hypothalamic tissues from PWS T1 and T2 individuals, conducting transcriptomic analyses and cell-specific protein profiling in white matter, neurons, and glial cells to unravel the cellular and molecular basis of phenotypic severity in PWS sub-genotypes. In PWS T1, key pathways for cell structure, integrity, and neuronal communication are notably diminished, while glymphatic system activity is heightened compared to PWS T2. The microglial defect in PWS T1 appears to stem from gene haploinsufficiency, as global and myeloid-specific Cyfip1 haploinsufficiency in murine models demonstrated. Our findings emphasize microglial phagolysosome dysfunction and altered neural communication as crucial contributors to the severity of PWS T1's phenotype.

Indexed as

Prader-Willi SyndromeAdaptor Proteins, Signal TransducingAnimalsCarrier ProteinsHumansMiceMicrogliaPhagosomesPhenotypeAdaptor Proteins, Signal TransducingCarrier ProteinsCyfip1 protein, mouseFornixGlymphatic systemHypothalamusImmunosurveillanceMicrogliaMyelinOxytocin

Identifiers

PMID38556574
PMCPMC10982101
OpenAlexW4393357086

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.